NOTE: ALL STOCKS IN THIS WATCHLIST ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. SEE TECHNICAL COMMENTS IN THE CHARETS. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE CONSIDERING INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com).
BSX: Shares float of 1.36 billion - it won't be a fast mover but should be a great long-term hold.
News - On September 25, 2017, Boston Scientific announced the launch of the Resonate family of ICD (implantable cardioverter defibrillator) and CRT-D (cardiac resynchronization therapy defibrillator) systems. The devices feature Boston Scientific’s HeartLogic Heart Failure Diagnostic system and are approved by the FDA for conditional use in the MRI (magnetic resonance imaging) environment.
Boston Scientific has a strong product portfolio and plans to launch key innovative products in high-growth markets to capture the untapped growth opportunities in such markets. The company aims to expand across high-growth adjacencies through locally relevant innovative products and solutions. By 2020, these markets are estimated to present ~$13 billion in incremental market opportunities for Boston Scientific.
APVO: Shares float of 17.23 million
News - APVO announced that it has amended the terms of a credit agreement initially executed with MidCap Financial Trust in August 2016. The first tranche of this term loan, in the amount of $20 million, was funded in August 2016. The amendment allows Aptevo to retain this $20 million funding tranche, for which repayment was anticipated coincident with the sale transaction of Aptevo’s hyperimmune commercial assets.
In addition, it announced that it has completed the sale of three of its marketed products (WinRho® SDF, HepaGam B®, and VARIZIG®) to Saol Therapeutics for total consideration of up to $74.5 million. The transaction is valued at up to $74.5 million, including an upfront payment of $65 million and an additional potential milestone payment of up to $7.5 million related to the achievement of gross profit milestones. In addition, Aptevo may receive up to $2 million related to the collection of certain accounts receivable. “The sale of our hyperimmune products is a transformative event for Aptevo that positions us well for future value creation by strengthening our financial position and sharpening our focus on our most promising commercial and pipeline assets,” said Marvin L. White, President, and Chief Executive Officer.
ABEO: Shares float of 23.57 million
News - ABEO announced on Thursday an update on the Company’s manufacturing strategy and plans for ABO-102, including strategic manufacturing commitments with Brammer Bio for commercial translation.
The company will also be participating in the following investor and industry conferences:
- Cell & Gene Meeting on the Mesa on October 4th-6th in La Jolla, CA
- The Jefferies 2017 Gene Therapy Summit on Thursday, October 12th at New York City, NY
- The European Society of Gene and Cell Therapy on October 17th-20th in Berlin, Germany
ELF: Shares float of 35.71 million
News - For what it's worth, in mid-September, Cramer said he likes this stock. But it took 2 weeks for the market to digest this. Now it's on fire. Up 5 straight days for over 18%. Since June, 2 more analysts have rated it a buy with a PT of 30.00 or 31% higher than Friday's closing price.